dc.contributor.author
Garcia-Guiñón, Antoni
dc.contributor.author
Abella Monreal, Eugenia
dc.contributor.author
Ben Azaiz, Ran
dc.contributor.author
Fernández de Larrea Rodríguez, Carlos José
dc.date.accessioned
2026-03-25T14:52:47Z
dc.date.available
2026-03-25T14:52:47Z
dc.date.issued
2026-03-24T17:43:51Z
dc.date.issued
2026-03-24T17:43:51Z
dc.date.issued
2026-03-24T17:43:51Z
dc.identifier
Garcia-Guiñon A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, Santaliestra M, Garcia-Pintos M, Gonzalez Y, Senin A, Motlló C, Abella E, Cabezudo E, Granell M, Sancho E, Herranz MJ, Seres Y, Gironella M, Soler JA, Marti-Tutusaus JM, Ben Azaiz R, Fernandez de Larrea C. Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma. Ann Hematol. 2025 Feb;104(2):1177-86. DOI: 10.1007/s00277-025-06240-1
dc.identifier
https://hdl.handle.net/10230/72894
dc.identifier
http://dx.doi.org/10.1007/s00277-025-06240-1
dc.identifier.uri
https://hdl.handle.net/10230/72894
dc.description.abstract
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Annals of Hematology. 2025;104(2):1177-86
dc.rights
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Carfilzomib, lenalidomide and dexamethasone
dc.subject
Relapsed/refractory multiple myeloma
dc.title
Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
